The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isIn phase 3.
- What to watchPersistent upper belly pain, especially after fatty meals.
How Survodutide works
Survodutide is a glucagon receptor and GLP-1 receptor dual agonist, and unlike the rest of this class it has a paper describing how the ratio was chosen.
What was measured instead, and it is unusually concrete. The two arms were each given their own in vivo readout. Area under the curve 54% versus vehicle for survodutide against 45% for semaglutide, so the GLP-1 arm is doing roughly what a selective GLP-1 does.
- Injectable
On the goal map: Hepatic fat & fatty liver (Metabolic health & insulin sensitivity)
Research on Survodutide6 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
In phase 3. Boehringer Ingelheim's GLP-1/glucagon dual agonist. Phase 2 reported around 19% mean weight loss at 46 weeks, placing it near tirzepatide territory.
The more distinctive phase 2 result was in MASH (fatty liver disease), where it achieved histological improvement in a large majority of patients — a harder endpoint than weight, requiring biopsy.
Correlative data
Not marketed anywhere; there is no real-world record. Trial tolerability looks like the class.
How the mechanism reads
Agonizes both GLP-1 and glucagon receptors, which sounds contradictory — glucagon raises blood sugar. The rationale is that glucagon also increases energy expenditure and drives hepatic fat oxidation, and GLP-1's glucose control offsets the glycemic downside.
MechanisticThat is why the liver result is the interesting one: burning hepatic fat is a glucagon action specifically, not something a pure GLP-1 does. The dual design predicts exactly the effect the MASH data showed.
MechanisticThe predicted cost of adding glucagon is a higher heart rate and greater reliance on getting the receptor ratio right.
Mechanistic
Sources
- Zimmermann T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism 2022 · PMID 36356832
- Thomas L, et al. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes, Obesity and Metabolism 2024 · PMID 38560764
- Jungnik A, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, Obesity and Metabolism 2023 · PMID 36527386
- Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine 2024 · PMID 38847460
- le Roux CW, et al. New England Journal of Medicine 2026 · PMID 42253238
- Zimmermann T, et al. Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. Molecular Metabolism 2026 · PMID 41638399
Survodutide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Medullary thyroid cancer, in you or a close relative, or MEN2: GLP-1 receptor agonists carry that rodent signal.
- Pancreatitis or symptomatic gallstones: stronger appetite loss speeds stone formation.
- Insulin or sulfonylurea treatment, since appetite loss and GLP-1 action both lower glucose.
- Decompensated liver disease: the glucagon arm acts on hepatocytes and is untested in a failing liver.
- Pregnancy or breastfeeding: dual incretin appetite suppression cuts the energy a pregnancy needs.
What’s expected
- Appetite suppression, with the glucagon arm adding energy expenditure and liver fat reduction.
- Nausea and reflux in the first weeks of any increase.
- Slightly higher resting pulse.
- Falling liver enzymes if you have fatty liver.
Watch for
- Persistent upper belly pain, especially after fatty meals.
- Yellow eyes, or dark urine with pale stools.
- Palpitations at rest.
- A neck lump or hoarse voice.
Labs that tell you it’s working
- Comprehensive Metabolic Panel (CMP)
- Lipase
- Enhanced Liver Fibrosis (ELF) Test
- HbA1c (Hemoglobin A1c)
Dual GLP-1 and glucagon agonist aimed at weight and fatty liver; pancreas, gallbladder and liver labs match its two arms. PMID 38847460 PMID 42253238
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel, explained
Survodutide FAQ4 common questions
- Is Survodutide approved for human use?
- No. Survodutide is a research compound.
- What is Survodutide researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Lipase; Enhanced Liver Fibrosis; HbA1c: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Survodutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




